Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Reporting at EULAR, researchers found that opioid use by patients with rheumatic and musculoskeletal pain was on the rise in Europe.

Whether it be fentanyl, tramadol or tilidine, new European figures show that increasingly more people are taking opioids for pain connected with rheumatic and musculoskeletal diseases.

The European League Against Rheumatism (EULAR) reported the findings at its recent virtual conference and warned of a growing risk of opioid abuse in Europe, calling for measures to use these analgesics more safely.

NDORMS DPhil Junqing Xie was lead author of a study that analysed the use opioids in patients with osteoarthritis in Catalonia, Spain from 2007 – 2016. Reviewing the health data of approximately six million patients, his research showed the use of the medication increased from 15 to 25 percent during that time.

"Taking opioids, in particular strong opioids, has substantially increased in recent years in patients newly suffering from osteoarthritis," said Junqing. "Precautions must urgently be taken so that these medications are prescribed safely."

The Catalonia study identified certain groups that showed an increased risk for addiction or dependency. Women were 4% more often affected than men, the elderly were 10% more affected than younger populations, and those with a lower socioeconomic status were 6% more likely to be affected than more privileged groups. Residents of rural areas were 1% more likely to take opioids compared to urban residents.

A separate study in Iceland not only showed that the taking of opioids frequently continues even after the source of pain has gone, but that their consumption actually increases. "It is a matter of urgency", says EULAR President Professor Iain B. McInnes from Glasgow, Scotland, UK.

Opioids are strong analgesics effective for patients with chronic non-tumor associated pains, such as chronic osteoarthritis. However, after a prescribed dose of treatment they should stop being taken. Their strong side effects include effects to the central nervous system which are sometimes mood enhancing. "This accounts for their strong addiction potential: For most patients, the physical withdrawal is therefore the most difficult," said Professor Ulf Müller-Ladner, EULAR Past Chair of Standing Committee on Clinical Affairs and Medical Director of the Rheumatology and Clinical Immunology Department of the Kerckhoff Clinic in Bad Nauheim, Germany.

The risk of physical and psychological addiction development is, however, low when opioids are used as intended. "Therefore, we would like to raise awareness of a responsible approach both by the prescribers and also the patients", says Professor John Isaacs from the University of Newcastle, UK, who is currently the EULAR Scientific Committee Chair.

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).